Imran Haider, Darryl P Leong, Omar Shahid, Martha Louzada, Arleigh McCurdy, Gregory R Pond, Ruthanne Cameron, Amaris K Balitsky, Joanne Britto, Mohammed Aljama, Alissa Visram, Tanya M Wildes, Hira Mian
{"title":"现实世界多发性骨髓瘤患者衰弱分类在一年内的变化:一项前瞻性队列研究(m虚弱)","authors":"Imran Haider, Darryl P Leong, Omar Shahid, Martha Louzada, Arleigh McCurdy, Gregory R Pond, Ruthanne Cameron, Amaris K Balitsky, Joanne Britto, Mohammed Aljama, Alissa Visram, Tanya M Wildes, Hira Mian","doi":"10.1016/j.clml.2025.09.007","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>While the distribution of frailty status in patients with multiple myeloma (MM) has been documented at a single time point, there is limited data examining how frailty changes over time in this population.</p><p><strong>Patients and methods: </strong>Patients aged > 18 years initiating treatment for newly diagnosed or relapsed MM between Aug 2021 and Jul 2023 across 3 sites in Ontario, Canada were enrolled. Frailty assessments were conducted at two time points (baseline and 12-months) using 4 frailty categorization tools: 1) the IMWG frailty index, 2) the Simplified frailty index, 3) the Mayo frailty index, and 4) the Fried frailty phenotype. At baseline and the 12-month follow-up, the frequency and proportion of patients were calculated for both frailty categorization (i.e., non-frail, frail) and continuous frailty scores (i.e., scores 0-5).</p><p><strong>Results: </strong>A total of 116 patients with newly diagnosed or relapsed MM were evaluated for frailty assessments at baseline and after a 12-month follow-up, using 4 different frailty indices. Changes in frailty status across the cohort varied from 13.8% to 37.1%, due to differences in how frailty was defined between each frailty index. In comparison, changes in continuous frailty score across the cohort varied from 20.7% to 51.7%. A total of 17.2% of patients experienced a reduction in gait speed of at least 0.1 m/s.</p><p><strong>Conclusion: </strong>This study demonstrates the dynamic nature of frailty highlighting that a one-time baseline frailty measurement may not be adequate. Additionally, continuous frailty scores may be more sensitive to early improvements/deteriorations in frailty that may go undetected using categorical frailty assessments.</p>","PeriodicalId":10348,"journal":{"name":"Clinical Lymphoma, Myeloma & Leukemia","volume":" ","pages":""},"PeriodicalIF":2.7000,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Changes in Frailty Categorization Over One Year among Real-World Patients With Multiple Myeloma: A Prospective Cohort Study (MFRAIL).\",\"authors\":\"Imran Haider, Darryl P Leong, Omar Shahid, Martha Louzada, Arleigh McCurdy, Gregory R Pond, Ruthanne Cameron, Amaris K Balitsky, Joanne Britto, Mohammed Aljama, Alissa Visram, Tanya M Wildes, Hira Mian\",\"doi\":\"10.1016/j.clml.2025.09.007\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>While the distribution of frailty status in patients with multiple myeloma (MM) has been documented at a single time point, there is limited data examining how frailty changes over time in this population.</p><p><strong>Patients and methods: </strong>Patients aged > 18 years initiating treatment for newly diagnosed or relapsed MM between Aug 2021 and Jul 2023 across 3 sites in Ontario, Canada were enrolled. Frailty assessments were conducted at two time points (baseline and 12-months) using 4 frailty categorization tools: 1) the IMWG frailty index, 2) the Simplified frailty index, 3) the Mayo frailty index, and 4) the Fried frailty phenotype. At baseline and the 12-month follow-up, the frequency and proportion of patients were calculated for both frailty categorization (i.e., non-frail, frail) and continuous frailty scores (i.e., scores 0-5).</p><p><strong>Results: </strong>A total of 116 patients with newly diagnosed or relapsed MM were evaluated for frailty assessments at baseline and after a 12-month follow-up, using 4 different frailty indices. Changes in frailty status across the cohort varied from 13.8% to 37.1%, due to differences in how frailty was defined between each frailty index. In comparison, changes in continuous frailty score across the cohort varied from 20.7% to 51.7%. A total of 17.2% of patients experienced a reduction in gait speed of at least 0.1 m/s.</p><p><strong>Conclusion: </strong>This study demonstrates the dynamic nature of frailty highlighting that a one-time baseline frailty measurement may not be adequate. Additionally, continuous frailty scores may be more sensitive to early improvements/deteriorations in frailty that may go undetected using categorical frailty assessments.</p>\",\"PeriodicalId\":10348,\"journal\":{\"name\":\"Clinical Lymphoma, Myeloma & Leukemia\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2025-09-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lymphoma, Myeloma & Leukemia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.clml.2025.09.007\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lymphoma, Myeloma & Leukemia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clml.2025.09.007","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
Changes in Frailty Categorization Over One Year among Real-World Patients With Multiple Myeloma: A Prospective Cohort Study (MFRAIL).
Background: While the distribution of frailty status in patients with multiple myeloma (MM) has been documented at a single time point, there is limited data examining how frailty changes over time in this population.
Patients and methods: Patients aged > 18 years initiating treatment for newly diagnosed or relapsed MM between Aug 2021 and Jul 2023 across 3 sites in Ontario, Canada were enrolled. Frailty assessments were conducted at two time points (baseline and 12-months) using 4 frailty categorization tools: 1) the IMWG frailty index, 2) the Simplified frailty index, 3) the Mayo frailty index, and 4) the Fried frailty phenotype. At baseline and the 12-month follow-up, the frequency and proportion of patients were calculated for both frailty categorization (i.e., non-frail, frail) and continuous frailty scores (i.e., scores 0-5).
Results: A total of 116 patients with newly diagnosed or relapsed MM were evaluated for frailty assessments at baseline and after a 12-month follow-up, using 4 different frailty indices. Changes in frailty status across the cohort varied from 13.8% to 37.1%, due to differences in how frailty was defined between each frailty index. In comparison, changes in continuous frailty score across the cohort varied from 20.7% to 51.7%. A total of 17.2% of patients experienced a reduction in gait speed of at least 0.1 m/s.
Conclusion: This study demonstrates the dynamic nature of frailty highlighting that a one-time baseline frailty measurement may not be adequate. Additionally, continuous frailty scores may be more sensitive to early improvements/deteriorations in frailty that may go undetected using categorical frailty assessments.
期刊介绍:
Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.